No | Author, year | Country | Enrolment criteria | Source of infection | Study design | Non-CBP agents | Compared therapy | Pathogen | Outcome | Result |
---|---|---|---|---|---|---|---|---|---|---|
#1 | Paterson, 2004 | Seven countriesa | BSI | UTI 14% | Prospective | Any | DT | KP | 28-day mortality | CBP was superior |
#2 | Lee, 2010 | Taiwan | BSI | UTI 7.4% | Retrospective | BL | DT | Enterobacter cloacae | Mortality | CBP was superior |
#3 | Rodriguez-Bano, 2012 | Spain | BSI | UTI and biliary tract infection 70% | Post-hoc analysis | BLBLI | ET, DT | EC | Mortality | NS |
#4 | Doi, 2013 | Japan | Bacteriuria | Only UTI | Retrospective | CMZ | Through ET and DT | Any | Clinical and microbiological cure | NS |
#5 | Kelvin, 2013 | China | BSI | UTI 44% | Retrospective | Any | ET, DT | EC | 30-day mortality | NS |
#6 | Park, 2014 | Korea | Pyelonephritis | Only UTI | Retrospective | Any | Through ET and DT | EC | Clinical failure | NS |
#7 | Tamma, 2015 | US | BSI | UTI 19% | Retrospective | PT | ET | Any | 14-day mortality | CBP was superior |
#8 | Harris, 2015 | Singapore | BSI | UTI 47% | Retrospective | BLBLI | DT | EC and KP | 30-day mortality | NS |
#9 | Matsumura, 2015 | Japan | BSI | UTI 45% | Retrospective | CMZ, FMOX | ET, DT | EC | 30-day mortality, clinical response | NS |
#10 | Lee, 2015 | Taiwan | BSI | UTI 23% | Retrospective | FMOX | DT | EC and KP | 30-day mortality | CBP was superior |
#11 | Tsai, 2015 | Taiwan | BSI | UTI 51% | Retrospective | PT | DT | Proteus mirabilis | 30-day mortality | NS |